이상혈색소증 시장 기회와 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Hemoglobinopathies Market was valued at USD 6.3 billion in 2023 and is anticipated to grow at a CAGR of 10.4% from 2024 to 2032, driven by a rise in hemoglobin associated diseases, developments in genetic research, and new therapeutic inventions. Hemoglobinopathies encompass genetic conditions such as sickle cell disease (SCD) and thalassemia that affect the structure and function of hemoglobin, the protein responsible for oxygen transport in red blood cells. This industry spans the diagnosis, treatment, and management of these inherited blood disorders, offering pharmaceuticals, gene therapies, diagnostic tests, and blood transfusion services aimed at both symptomatic relief and potential cures. The market is segmented by disease type into categories like thalassemia and SCD, with thalassemia further divided into alpha and beta forms.

In 2023, SCD accounted for the largest share of the market, valued at USD 3.3 billion. Treatments for SCD include blood transfusions, pain management, and hydroxyurea, with promising advancements in gene therapy and CRISPR-based approaches. Support from the pharmaceutical sector and government funding is fostering the development of innovative treatment options. In terms of treatment type, the market is divided into blood transfusion, hydroxyurea, iron chelation therapy, bone marrow transplant, and other methods.

Blood transfusions represented a notable 43.1% of the market in 2023 and remain a crucial treatment, especially in conditions like thalassemia and SCD. This therapy involves the regular transfusion of healthy red blood cells to alleviate anemia, minimize complications, and improve patients' quality of life. Blood transfusion therapy is particularly vital in developing regions, where advanced treatment options may be less accessible. Regionally, North America is poised to grow at 10% CAGR through 2032, with the market expected to reach USD 5.7 billion.

U.S. hemoglobinopathies market growth is supported by enhanced awareness, early diagnosis, and the adoption of advanced treatments for conditions like SCD and thalassemia. The region's strong healthcare infrastructure facilitates rapid integration of cutting-edge diagnostic technologies, including gene therapies and next-generation sequencing. Government-led initiatives, such as newborn screening programs, are also improving early detection rates, significantly boosting patient outcomes. With a growing demand for effective treatments and increased government and industry investment in advanced therapies, the hemoglobinopathies market is set for substantial expansion.

This growth aligns with global efforts to improve the diagnosis, treatment, and overall management of these life-impacting blood disorders.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hemoglobinopathies
    • 3.2.1.2 Advancement in diagnostic technologies
    • 3.2.1.3 Emerging gene therapies and stem cell transplantation
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with treatment
    • 3.2.2.2 Side effects associated with treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Thalassemia
  • 5.2.1 Alpha thalassemia
  • 5.2.2 Beta thalassemia
• 5.3 Sickle cell disease
• 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Blood transfusion
• 6.3 Hydroxyurea
• 6.4 Iron chelation therapy
• 6.5 Bone marrow transplant
• 6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 bluebird bio
• 9.2 Bristol-Myers Squibb Company
• 9.3 CHIESI FARMACEUTICI
• 9.4 Emmaus Medical
• 9.5 Medunik USA
• 9.6 Novartis
• 9.7 Pfizer
• 9.8 Prolong Pharmaceuticals
• 9.9 Teva Pharmaceuticals Industries
• 9.10 Vertex Pharmaceuticals Incorporated